Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q1 2019 · 10-Q
Revenue$1.48M$1.48M+2,692.6% vs Q1 2018 Net Income-$512.00K-$512.00KN/M vs Q1 2018 EPS Diluted-$0.02-$0.02N/M vs Q1 2018 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
Operating Cash Flow-$535,000N/M Free Cash Flowderived-$538,000N/M Margins · derivedGross margin2.8%
Operating margin-34.6%+714.1 pt vs Q1 2018
Net margin-34.6%+781.9 pt vs Q1 2018
ended Jun 30, 2018 · filed Aug 3, 2018 · 34 d after period end